SanaClis CRO – Founded in 2000, SanaClis is a full-service global CRO with strong in-house clinical supply chain, logistics, and sourcing capabilities. We support clinical trials worldwide across the full study lifecycle and can operate as either a full-service or functional service provider, depending on sponsor needs. We have delivered clinical trial projects for sponsors ranging from virtual biotech to top 10 pharmaceutical companies, combining operational rigor with responsive execution and a focus on quality and predictable delivery. SanaClis provides CRO and clinical supply chain services across all therapeutic areas, with coverage across Europe (including the UK), USA (Americas) and Asia. We also bring deep operational experience in Central and Eastern Europe (CEE), supporting strong patient access and reliable site performance. To enable global distribution, SanaClis operates a network of privately owned, GMP- and GDP-certified depots strategically located worldwide. Our facilities support ambient and cold-chain storage, as well as packaging, labeling, and distribution services to protect product integrity throughout the IMP cold chain. CRO Services: Project Management, Clinical Monitoring, Site Management, Regulatory, Medical Writing, Data Management, Biostatistics, Pharmacovigilance, Medical Monitoring, Quality Management, Decentralized Trials. Clinical Supply Chain Services: Storage and Distribution, Secondary Packaging and Labelling, Global Strategic Sourcing, Qualified Person Services, Customs and Brokerage, SIMS – Inventory Management, Direct to Patient Services. Please reach out to Matt Delaney, Vice President of Business Development for the Americas region, email: matt.delaney@sanaclis.com or by phone at: 1 805 798-0060. Matt resides in San Diego, Ca.
RudaCure
RudaCure is a clinical-stage biotechnology company dedicated to developing innovative treatments for incurable diseases with sensory based disorders and high unmet medical needs. | RudaCure is a clinical-staged biotech company dedicated to developing innovative first-in-class treatments for incurable diseases with sensory based disorders and high unmet medical needs. RudaCure’s multi-indication pipeline include treatments for dry eye and chronic pain.
Resolian
Resolian is a leading global Contract Research Organization (CRO) providing specialized services in GxP and non-regulated bioanalysis, drug metabolism/pharmacokinetic (DMPK), and GMP CMC analytical and materials science. Comprised of the former Alliance Pharma Inc, Drug Development Solutions Ltd, and Denali Medpharma labs and powered by a team of more than 500 experts across the US, UK, Australia, and China, Resolian supports pharma and biotech companies’ programs throughout the entire drug development continuum. Resolian’s specialized solutions include small and large molecule LC-MS/MS bioanalysis, PK immunoassays for large molecules, immunogenicity, biomarkers, cell-based assays, and drug metabolism. These solutions are delivered through Resolian’s dedicated global laboratories, equipped with state-of-the-art technology and ready to meet client needs for preclinical studies as well as regional or global clinical programs. We are committed to delivering high-quality results and ensuring compliance with regulatory requirements. Its team of experts works closely with clients to develop customized solutions for each specific program requirements. A trusted partner for pharmaceutical and biotech companies seeking specialized support in drug development, Resolian’s extensive expertise, advanced technology, and commitment to quality combine to fully deliver for companies of all sizes and at any stage of the drug development process.
ProJect Pharmaceutics (PJP)
PJP is the go-to specialist in formulation and process development across complex biologics, bioconjugates, and other therapeutic modalities. Our development agility spans liquid, frozen, and lyo formats in vials, cartridges, or pre-filled syringes and in-step or independent from your chosen manufacturer. Let’s solve your formulation and process challenges together.
Preclina Inc
Immune Specialists’ Research Service CRO: [ Booth # 4158] Preclina is a non-clinical CRO with a fully-integrated drug discovery platform specializing in Immunology. We offer a portfolio of models for efficacy pharmacology studies in autoimmunity, immuno-oncology, and transplantation immunology. Our platforms include humanized mouse models recapitulating autoimmune diseases and humanized tumor xenografts, enabling preclinical evaluation of biologics, cell therapies, and novel immunotherapies. With over 20 years of expertise in immunology, immunotoxicology, and bioanalysis, Preclina delivers integrated, customizable solutions with a focus on scientific rigor, speed, and cost-efficiency. Our advanced approaches help accelerate drug discovery and reduce development risk. We serve as a “Bridging Specialist” connecting non-clinical and clinical stages, supporting biotech and pharma partners in optimizing pipelines and making faster, smarter decisions in immunology drug development. Meet us at Booth # 4158. Our Preclinical Services: ● Comprehensive in vivo efficacy pharmacology services utilizing well-established autoimmune and inflammatory disease models, augmented by pioneering, technically advanced humanized autoimmune disease model platforms ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and the fastest results [PreVIVO™ Platform] Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Autoimmune Specialists’ Research Service CRO: Preclina is a non-clinical CRO specialized in autoimune and inflammatory disorders, providing the utmost quality services for novel drug development at the lightning speed, highest quality, and reasonable cost. In the global market of immune disease therapeutics, which shows explosive growth, Preclina Inc is a leading company that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. [Our preclinical services] ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results (Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA) ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Preclina is a global leading non-clinical CRO that supports bio and pharmaceutical companies to secure new drug development competitiveness by providing the highest quality evaluation results at the fastest speed for the optimization processes of candidate compounds. Our scientific expertise in autoimmune and inflammatory diseases has been accumulated over 20 years. Scientists in Preclina provide well-established service repertoire mostly based on therapeutic efficacy evaluation, and effectively designed support for drug development processes. We’re strengthening our leadership in immunological research by broadening our portfolio with sophisticated humanized mouse models, specifically optimized for oncology drug development. We strive to satisfy our clients by providing innovative integrated modular platform of investigation that permits robust results with lightning speed. Our preclinical services: ● In vivo efficacy pharmacology using disease models recapitulating autoimmune and inflammatory disorders ● Humanized mouse models for immunotherapeutic development and pathogenesis research in oncology and transplantation immunology fields ● Cell-based assays using patient-derived cells isolated from immune diseases ● Modular platform services for consistent and fastest track results Modules: PreCIATa, PreBILFi, PreNASHa, PrePsora, and PreEXA ● Premium Platform services integrating modular platform and patient-derived cellular assays which encompasses from lead selection to candidate development, thus dramatically reducing late failure rate of drug discovery | Immune Specialists’ Research Service CRO: [ Booth #3816] Predict Your Clinical Success with “World’s First” Humanized Models Preclina is a “Bridging Specialist” that eliminates the uncertainty of the translational gap. We provide the high-fidelity data needed to turn early-stage assets into clinical success stories. 1. Proven Excellence in Immunology – Expertise: Over 20 years specializing in immunology, immunotoxicology, and bioanalysis. – Track Record: Contributed to $600M+ global license-out deals. – Reliability: Supported multiple assets achieving final FDA approval. 2. The PreHu™ Advantage: Unrivaled Predictive Power Gain an exclusive competitive edge with our quartet of World’s First & Pioneering commercialized humanized disease models: – World’s First Lineup: Our peer-reviewed models for Psoriasis, Atopic Dermatitis, BILF, and DSS-induced Colitis are the first of their kind commercialized globally. – Peer-Reviewed Authority: All four models are published in leading journals, ensuring high reproducibility and scientific rigor. – Translational Relevance: These platforms recapitulate the human immune system in a patient-like environment to accurately validate biologics and cell therapies. 3. Operational Speed & Strategy PreVIVO™ Platform: Access modular services (PrePsora, PreBILFi, PreNASHa, etc.) for the fastest, most consistent data. – Risk Reduction: Integrated services encompass lead selection to candidate development, dramatically reducing late-stage failure rates. – Strategic Grant: The PreTrial™ Program offers exclusive grant support to qualified companies to bridge the “PoC Hurdle” and boost asset valuation. Consult with our Global Business Development team to de-risk your pipeline today [ Humanized Mouse Model Platform (PreHu™) ] 1. Humanized CDX/PDX (Patient-Derived Xenograft)-Based Efficacy Services : This platform implants tumor cells/tissues into humanized mice for bio-pharmaceutical efficacy evaluations in a patient-like environment, crucial for immuno-oncology and cell therapy assessments. – Humanized CDX/PDX Model – Humanized PBMC/HSc Model – GvHD Model 2. Humanized Autoimmune Disease / Fibrosis Mouse Model : We have pioneered the world’s first service platform with four or more humanized autoimmune disease models, providing essential preclinical services for the development of biopharmaceuticals, such as antibody drugs and cell therapies. – Humanized Ulcerative Colitis (UC) Model – Humanized Pulmonary Fibrosis (IPF) Model – Humanized Psoriasis Model – Humanized Atopic Dermatitis Model [Efficacy Evaluation Pharmacology Services (PreVIVO™) ] 1. Arthritis Research Service: Preclina’s service not only includes all essential models for evaluating the efficacy in the development of therapeutic agents for rheumatoid arthritis but also provides the key model for osteoarthritis – CIA Model / CAIA Model / ACLT Model 2. Fibrosis Research Service: With extensive expertise in immunology and fibrosis research, we have the flexibility to lead drug efficacy assessment projects with in-depth insights, maximizing the potential for success in new drug development. – BILF Model / BISF Model / MASH Model 3. Atopic Dermatitis & Psoriasis Research Service: Preclina provides specialized inflammatory skin disease models to support preclinical and mechanistic research in dermatology. These models include psoriasis, atopic dermatitis, and hypersensitivity disorders, enabling precise evaluation through mRNA analysis, protein assays, histopathology, and cellular assessments. With internationally standardized read-outs and customized research services, our models enhance the success rate of new drug development. – Imiquimod-Induced Psoriasis / IL-23-Induced Psoriasis Models – Oxazolone-Induced AD / House Dust Mite-Induced AD Models 4. Inflammatory Bowel Disease Research Service : Preclina provides specialized models for inflammatory bowel disease (IBD) research. These models include the ulcerative colitis model (Dextran Sodium Sulfate, DSS-induced colitis) and the Crohn’s disease model (Dinitrobenzene Sulfonic Acid, DNBS-induced colitis). These models accurately replicate disease onset and progression, enabling comprehensive disease activity index (DAI) assessments, histopathologic evaluations, biomarker analyses, and toxicity assessments. – DSS-Induced Colitis / DNBS-Induced Colitis Models 5. Lupus Research Service: Preclina provides key animal models for lupus and Sjogren syndrome research. For lupus, it supports the development of new drugs targeting B lymphocytes, cell surface molecules, signaling pathway proteins, and regulatory cytokines. It also offers a mouse model for Sjogren syndrome. – MRL/lpr Lupus Model / NZBW F1 Lupus Model 6. Neuroscience Research Service: Preclina provides a specialized EAE (Experimental Autoimmune Encephalomyelitis) animal model to support preclinical research and mechanistic studies on multiple sclerosis (MS). In particular, the MOG-induced EAE mouse model serves as a standard model that closely resembles the inflammatory pathogenesis of MS driven by autoimmune mechanisms, making it widely utilized for evaluating disease progression and treatment responses. – MOG EAE Model / PLP EAE Model [Non-GLP Toxicology service & ADME-PK ] Customized PK/ADME-Tox evaluation services for dramatically enhancing the potential for successful drug development.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
Phase Clinical Services
Your complete resource for oncology clinical trials and biospecimens | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies. Our clients are pharma and biotech companies from startup to the top-ten level, assay developers, high-end academic institutions, and the U.S. government. We maintain an FDA-registered cell isolation lab in Milwaukee and an in-house pathology service. | Phase Clinical Services is a biospecimen provider headquartered in the New York area which specializes in science-driven and large-scale projects. Utilizing our global network of collection sites, we provide a wide range of materials, such as tumor tissue, blood products, FFPE blocks, cell preparations (e.g. PBMCs, CD34 cells), bulk plasma etc. We cover indications for oncology, infectious diseases, autoimmune conditions, many other disorders, as well as healthy volunteer studies.
Novotech
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations. Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
NONA BIOSCIENCES
Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models. | Nona Biosciences is a Boston-based Biotechnology company specialized in fully human antibody discovery. Harbour Mice®, our proprietary technology, are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform produces human Vh single domain antibodies, providing multiple advantages for bispecific and multispecific antibody engineering | Nona Biosciences is a Boston-based Biotech company specialized in fully human therapeutic antibody technology. Our proprietary Harbour Mice® technology are fully human transgenic mice platforms for either conventional fully human antibody (H2L2) or heavy chain only (HCAb) antibody discovery, engineering, and development. The HCAb platform is fully optimized and clinically validated with global patented protection. Nona Biosciences can provide comprehensive antibody discovery services from Idea to IND, which range from Beacon® Single B Cell Cloning, display technology to functional screening, characterization, in vivo efficacy assessment, antibody engineering, and CMC for clinical candidate generation. | Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models. Nona Biosciences is a biotechnology company offering integrated solutions for antibody discovery and development. Leveraging our proprietary Harbour Mice® platforms, which generate fully human H2L2 and heavy chain-only antibodies (HCAbs), we enable a broad range of therapeutic formats with high developability and flexibility. Nona’s HCAbs are the first and only clinically validated, fully human heavy chain-only antibodies on the market, offering advantages such as low immunogenicity, high solubility, and strong biophysical properties. Our H2L2 Open Access Platform enables rapid entry into discovery, while Modalities-on-Demand™ provides tailored support for bispecifics, TCEs, and other next-generation modalities including ADCs, CAR-T, and mRNA-based therapies. With capabilities spanning immunization, screening, engineering, and IND-enabling services, Nona empowers partners to move efficiently from idea to IND with flexibility and confidence. Our platforms have supported more than 300 discovery programs and over 19 partner INDs through a variety of collaboration models.